Table 1

Select baseline demographic and disease characteristics

Characteristic*All patients with I/P risk13Patients with I/P-risk sRCC9
NIVO+IPISUNNIVO+IPISUN
(N=425)(N=422)(n=74)(n=65)
Median age (range), years62 (26–85)61 (21–85)58 (35–84)61 (39–79)
Sex, n (%)
 Male314 (74)301 (71)55 (74)48 (74)
 Female111 (26)121 (29)19 (26)17 (26)
IMDC prognostic score, n (%)
 Intermediate (1–2)334 (79)333 (79)54 (73)48 (74)
 Poor (3–6)91 (21)89 (21)20 (27)17 (26)
Region, n (%)
 USA112 (26)111 (26)34 (46)19 (29)
 Canada/Europe148 (35)146 (35)20 (27)29 (45)
 Rest of the world165 (39)165 (39)20 (27)17 (26)
Prior nephrectomy, n (%)341 (80)319 (76)66 (89)54 (83)
No of sites with target/nontarget lesions,† n (%)
 190 (21)84 (20)15 (20)16 (25)
 ≥2335 (79)337 (80)59 (80)49 (75)
Most common sites of metastasis,ठn (%)
 Lung294 (69)296 (70)58 (78)50 (77)
 Lymph node190 (45)216 (51)36 (49)36 (55)
 Bone¶95 (22)97 (23)16 (22)13 (20)
 Liver88 (21)89 (21)10 (14)8 (12)
Quantifiable tumor PD-L1 expression, n (%)n=384n=392n=71n=62
 <1%284 (74)278 (71)35 (49)29 (47)
 ≥1%100 (26)114 (29)36 (51)33 (53)
  • *Information shown in the table is based on data collected with the use of an interactive voice-response system.

  • †The number of target or nontarget lesions at baseline was not reported for one patient in the SUN group.

  • ‡Patients may have lesions at more than one site.

  • §Includes both target and nontarget lesions.

  • ¶Includes bone with and without a soft-tissue component.

  • IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; I/P, intermediate/poor; NIVO+IPI, nivolumab plus ipilimumab; PD-L1, programmed death ligand 1; sRCC, sarcomatoid renal cell carcinoma; SUN, sunitinib.